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Objective: Cartilage and bone damage in rheumatoid arthritis (RA) are associated 
with elevated IL-1β. The effects of IL-1β can be reduced by biological therapies that 
target IL-1β or TNFα. However, the mechanisms responsible for increased IL-1β and 
the effect of anti-TNFα have not been fully elucidated. Recently, sterile-α and 
armadillo motif-containing protein (SARM) was identified as a negative regulator of 
toll-like receptor (TLR) induced IL-1β secretion through an interaction with the 
inflammasome. This study set out to investigate SARM during TLR induced IL-1β 
secretion in RA peripheral blood monocytes and in patients commencing anti-TNFα 
treatment. 
Methods: Monocytes were isolated from RA patients and healthy controls; disease 
activity was measured by DAS28. IL-1β secretion was measured by ELISA following 
TLR1/2, TLR4 and TLR7/8 stimulation. The mRNA expression of SARM, IL-1β and 
the components of the NOD-like receptor family, pyrin domain containing 3 (NLRP3) 
inflammasome were measured by quantitative PCR. SARM protein expression was 
measured by western blotting. 
Results: TLR1/2 activation induced elevated IL-1β in RA monocytes compared to 
heathy controls (P=0.0009), which negatively correlated with SARM expression 
(P=0.0086). Lower SARM expression also correlated with higher disease activity 
(P=0.0246). Additionally, patients responding to anti-TNFα treatment demonstrated a 
rapid upregulation of SARM, which was not observed in non-responders. 
Conclusion: Together, these data highlight a potential contribution from SARM to 












with RA pathogenesis. Furthermore, the data additionally present a potential 














Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with 
persistent inflammation of the synovial joints. Elevated production of pro-
inflammatory cytokines leads to articular damage, together with cardiovascular, 
metabolic and neurological comorbidities [1]. IL-1β, TNFα and IL-6 are key cytokines 
involved in sustaining RA pathogenesis. Targeting these cytokines with biological 
therapies can reduce inflammation and suppress joint damage [2]. The biologics that 
target TNFα are the most widely used as treatments for RA and they can also result 
in a reduction in IL-1β [3-5]. However, direct inhibition of IL-1β has proven to be less 
effective than targeting TNFα, producing only moderate benefit, so tends to be rarely 
used for clinical treatment of RA. Although, IL-1β does not appear to have a pivotal 
role in controlling inflammation in RA, it contributes to synovial joint damage and may 
have a role in comorbidities such as type 2 diabetes and cardiovascular disease [6]. 
Within the joint, IL-1β activates osteoclasts and chondrocytes leading to cartilage 
erosion and bone resorption [7].  
Monocytes recruited from the peripheral blood that differentiate into synovial tissue 
macrophages are considered to be the main source of IL-1β [8]. The secretion of IL-
1β involves several processes; transcriptional upregulation of pro-IL-1β is first 
induced in response to cell stimulation, followed by proteolytic cleavage of pro-IL-1β 
by caspase-1, a component of the NOD-like receptor family, pyrin domain containing 
3 (NLRP3) inflammasome, to produce biologically active IL-1β [9]. Caspase-1, once 
activated, additionally cleaves gasdermin D, freeing the N-terminus to oligomerize 
forming a pore in the cell membrane, permitting the release of IL-1β and inducing 
pyroptosis [10, 11]. Further regulation comes from sterile-α and armadillo motif-












inflammasome, suppressing the maturation of IL-1β [12]. Murine cells and human 
macrophages require two separate signals to produce mature IL-1β, one to induce 
transcription of pro-IL-1β and a second signal to activate the inflammasome. 
However, human monocytes can secrete IL-1β through toll-like receptor (TLR) 
activation alone in a pyroptosis independent manner [13].  
A potential pathway for the induction of IL-1β in RA is through activation of TLRs. 
This family of pattern recognition receptors has been suggested to contribute to the 
chronic inflammation characteristic of both human disease and experimental animal 
models of RA [14]. Indeed, the RA joint contains many endogenous TLR ligands 
such as Tenascin-C and anti-citrullinated peptide antibody (ACPA) immune 
complexes containing citrullinated fibrinogen, which can activate TLR4 [15, 16].  
Furthermore, ACPAs purified from RA patient serum can additionally induce NLRP3 
dependent IL-1β release from human granulocyte-macrophage colony-stimulating 
factor derived macrophages [17].  
Although many studies have demonstrated a contribution of IL-1β to RA 
pathogenesis, the underlying processes leading to increased IL-1β production in RA 
remain less well defined. The aim of this study was to investigate the relationship of 
SARM to IL-1β secretion in RA pathogenesis. SARM expression was examined in 
peripheral blood monocytes prior to stimulation with TLR ligands. RA patients with 
active disease expressed lower levels of SARM compared to healthy volunteers. 
SARM expression inversely correlated with RA disease activity and IL-1β release 
upon TLR1/2 activation. Furthermore, RA patients who responded to anti-TNFα 
therapy exhibited a transient increase in SARM that was not observed in non-
responders, providing a possible mechanism by which TNFα blockade additionally 












RA pathophysiology where decreased SARM may contribute to the elevated level of 
IL-1β associated with RA pathogenesis.  
 
Materials and methods 
Patient samples 
The study was approved by the Brighton East Research Ethics Committee 
(10/H1107/8), NRES committee South East Coast- Brighton and Sussex 
(11/LO/1320) and the NRES Committee North West–Lancaster (14/NW/1114). 
Patients were diagnosed by a consultant rheumatologist guided by the European 
League Against Rheumatism/American College of Rheumatology 2010 criteria for 
RA and recruited during a routine rheumatology clinic assessment. Healthy controls 
were recruited through the Brighton and Sussex University Hospitals Trust. The 
study complies with the Declaration of Helsinki. All participants provided informed 
written consent. Characteristics of the donors included throughout this study are 
summarised in table 1. Samples were collected over a 10-year period, consequently 
the number of RA patients receiving biological therapies within this study are lower 
than would be observed in current clinical practice. 
Cell Culture 
Whole venous blood was collected into tubes containing 1.8mg/ml (K2) EDTA 
(Becton Dickinson, Oxford, UK) and stored at room temperature for up to 2 hours 
prior to cell separation. Leukocyte cones from blood donors were purchased from 
NHS Blood and Transplant (Tooting, UK) to perform the experiments in figure 4B. 
Peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Paque 












from PBMCs derived from whole venous blood were isolated using CD14+ selection 
beads (Miltenyi Biotec, Cologne, Germany) as per the manufacturer’s instructions. 
Peripheral blood monocytes from PBMCs derived from leukocyte cones were 
isolated by iso-osmotic Percoll gradient centrifugation, as previously described [19], 
before being cultured in RPMI1640 media supplemented with 5% (v/v) foetal calf 
serum and 1% (v/v) penicillin/streptomycin solution (PAA, Pasching, Austria) with or 
without 100ng/ml PAM3CSK4 (Axxora, Nottingham, UK), 10ng/ml lipopolysaccharide 
(LPS) or 2μg/ml resiquimod (R-848) at 37°C, 5% CO2. All TLR ligands were used at 
predetermined concentrations that induce maximal cytokine induction. 
Quantitative Polymerase Chain Reaction (qPCR) 
RNA was extracted from CD14+ monocytes using a miRNeasy Mini Kit (QIAGEN, 
Stockach, Germany) according to manufacturer’s instructions and reverse 
transcribed using a High Capacity cDNA Reverse Transcription kit (Applied 
Biosystems, Paisley, UK) according to manufacturer’s instructions. The cDNA was 
analysed using Taqman qPCR assays (Life Technologies, Carlsbad, USA) using 
Taqman PCR master mix 2x (Thermo Fisher Scientific, Waltham, MA, USA). The 
level of SARM1 (assay: Hs00248344_m1), PYCARD (Hs00203118_m1), CASP1 
(Hs00354836_m1), NLRP3 (Hs00918082_m1) and IL1B (Hs00174097_m1) were 
determined relative to the geometric mean of the housekeeping genes GAPDH 
(Hs02758991_g1) and HPRT1 (Hs02800695_m1). Reactions were performed using 
a Stratagene MX3000P thermocycler or an Agilent AriaMX thermocycler (Agilent 
Technologies, Cheshire, UK) as per manufacturer’s instructions. Agilent Aria 1.6 
software (Agilent Technologies) was used for data collection and analysis. The 













Enzyme linked immunosorbent assays (ELISA) 
The concentration of IL-1β in cell culture supernatants was determined using an 
ELISA DuoSet (R&D Systems, Abingdon, UK) following the manufacturers’ 
instructions. Recombinant IL-1β standard was purchased from PeproTech (London, 
UK). Detection was performed using streptavidin-HRP (R&D systems, Minneapolis, 
USA) and a chromogenic TMB substrate (KPL, Gaithersburg, USA). Absorbance 
was read and analysed at 450nm on a spectrophotometric plate reader (BioTek 
Synergy HT, Winooski, USA) using the Gen5 version 1.08.4 software. 
Western blotting 
Monocytes were lysed in NP-40 buffer and protein concentrations were determined 
using bicinchoninic acid (BCA) protein assay kit (Life Technologies, Paisley, UK) 
according to the manufacturer’s instructions. Proteins were boiled in Laemmli buffer  
at 95°C for 5 minutes before resolved by SDS-PAGE using 10% Tris-glycine gels 
and transferred onto methanol activated Polyvinylidene difluoride membranes (Life 
Technologies)  After transfer, membranes were blocked with 3-5% BSA in 
Phosphate-buffered saline (PBS) with 0.1% Tween-20 (Fisher Scientific, 
Loughborough, UK) (PBS-T) for 1h at room temperature, and incubated overnight at 
4°C with the following primary antibodies diluted in 3-5% BSA in PBS-T; anti-SARM 
at 1:1000 (ProSci, Poway, USA), anti-GAPDH at 1:3000 (Cell Signalling, London, 
UK). A secondary anti-rabbit HRP-conjugated antibody (Sigma-Aldrich, Gillingham, 
UK) was used for detection. For protein visualisation, blots were incubated with 
Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare, Little 
Chalfont, UK). Membranes were then removed from the ECL solution and exposed 












Konica Minolta SRX-101A film developer and Champion Photochemistry film 
developer and fixer solutions (Jet X-ray, London, UK).   
Statistics 
Mean, standard deviation (SD), standard error of the mean (SEM) and statistical 
significance were calculated using GraphPad version 8 (GraphPad Software Inc., 
California, USA). For statistical analysis parametric data were compared using a two 
tailed unpaired t-test with Welch's correction, or a two-tailed paired t-test. Non-
parametric data were compared with a two tailed Mann Whitney U test. One-way 
ANOVA using Dunnett´s multiple comparisons test was applied for the comparison of 
multiple datasets relative to a control for parametric distributed variables. Correlation 
analysis was performed using a Pearson two-tailed test for parametric data and the 
Spearman’s test for non-parametric data. SEM was used for pooled experimental 
data. Multivariable linear regression analysis was performed in SPSS version 26 
(SPSS Inc., Chicago/IL, USA). Significance is shown as ****P<0.0001, ***P<0.001, 
**P<0.01 and *P<0.05. 
 
Results 
IL-1β production was elevated from RA monocytes upon TLR1/2 activation  
To assess the capability of TLRs to induce IL-1β from RA monocytes, peripheral 
blood CD14+ monocytes from RA patients and healthy controls (HCs) were 
stimulated with Pam3CSK4 to activate the TLR1/2 heterodimer, lipopolysaccharide 
(LPS) to stimulate TLR4 and R-848, a ligand that can activate both TLR7 and TLR8 
(Fig. 1). A significant elevation of IL-1β secretion was observed following TLR1/2 












but surprisingly this was not observed from cells activated with LPS or R-848 (Fig. 
1B and C). The elevated IL-1β upon TLR1/2 activation was not associated with 
treatment of either methotrexate or glucocorticoids (Supplemental Figure S1A). 
SARM expression was elevated in RA monocytes and inversely correlated with 
the level of TLR1/2 induced IL-1β release 
To explore this enhancement of IL-1β secretion from RA monocytes, the gene 
expression of inflammasome components NLRP3 (gene name NLRP3), pro-
caspase-1 (gene name CASP1), apoptosis-associated speck like protein containing 
a caspase recruitment domain (ASC) (gene name PYCARD) and the NLRP3 
inhibitor SARM (gene name SARM1) were measured. Equivalent expression of 
NLRP3, CASP1 and PYCARD were observed between HC and RA monocytes (Fig. 
2A, B and C, respectively). By contrast, increased expression of SARM1 was evident 
in monocytes from RA patients, relative to HC (P=0.0054) (Fig. 2D). The level of 
SARM1 expression was not associated with treatment of either methotrexate or 
glucocorticoids (supplemental Figure S1B). However, a wide range of expression 
was observed within the RA samples for all of these genes, with some donors 
exhibiting similar levels of expression to HCs whilst others demonstrated a 
substantially increased expression.  
These data were then compared with the TLR1/2 induced IL-1β secretion from RA 
patient monocytes to explore if the varying levels of gene expression correlated with 
TLR1/2 induced IL-1β. No association was observed between NLRP3, CASP1 or 
PYCARD and IL-1β secretion (Fig. 3A, B and C). However, an inverse relationship 
was observed between the basal expression of SARM1 in unstimulated cells and 












observed for TLR4 or TLR7/8 induced IL-1β secretion (Supplemental Figure S2). 
Multivariable linear regression analysis confirmed the association of SARM1 with the 
level of IL-1β secretion upon TLR1/2 activation (Supplemental Table S1). 
SARM was upregulated in response to activation of TLR4 and TLR8, but not 
TLR1/2  
The study that identified SARM as a negative regulator of the NLRP3 inflammasome 
demonstrated that SARM controlled IL-1β maturation but not the production of pro-
IL-1β (gene name IL1B) in murine bone marrow derived macrophages [12]. To verify 
that SARM was regulating TLR1/2 induced IL-1β through this NLRP3 dependent 
action and not by an alternative mechanism, basal expression of SARM1 was 
compared to the transcriptional expression of IL1B induced upon TLR1/2 activation. 
In agreement with the original study, SARM1 did not correlate with IL1B expression 
(Fig. 3E). However, it remained unclear as to why TLR1/2 induced elevated IL-1β 
secretion which correlated with SARM1 in the RA monocytes, while TLR4 and 7/8 
produced equivalent levels of IL-1β to HCs (Fig. 1). Negative regulators of 
inflammatory signalling cascades are often expressed in response to cell activation 
to restore the cell to a state of homeostasis [20]. To explore if SARM1 was 
upregulated in response to TLR activation, monocytes from healthy donors were 
cultured with Pam3CSK4, LPS or R-848 to measure the fold change in SARM1 
following stimulation. Both LPS and R-848 significantly upregulated SARM1 
expression (P=0.007 and P<0.0001, respectively), while TLR1/2 stimulation did not 
significantly affect expression (Fig. 3F).  












IL-1β has long been associated with RA pathogenesis leading to cartilage and bone 
erosion [21]. As lower SARM1 expression was associated with elevated IL-1β 
release from RA monocytes (Fig. 3D), SARM1 expression was next correlated with 
the disease activity score in 28 joints (DAS28), a clinical measure of RA disease 
activity [22]. Expression of SARM1 in RA monocytes was inversely correlated with 
DAS28 (P=0.0246, R=-0.4776, Fig. 4A). Multivariable linear regression analysis 
confirmed the association of SARM1 with DAS28 (Supplemental Table S1). By 
comparison, no significant associations between DAS28 and expression of 
PYCARD, CASP1 or NLRP3 were observed (Fig. 4B, C and D). To confirm the 
relationship between SARM1 and RA disease activity, SARM protein expression was 
analysed in monocyte lysates from HCs and RA patients over a range of DAS28 
scores. DAS28 can be used to categorize RA disease activity scores into groups, 
with scores of <2.6 representing patients in remission, 2.6 to <3.2 as low disease 
activity, 3.2 to ≤5.1 as moderate disease activity and scores >5.1 as high disease 
activity [23]. SARM protein levels were similar between RA donors in disease 
remission and healthy controls; by comparison, SARM protein was not detected in 
monocytes from RA donors with active disease (Fig. 4E).  
Patients that respond to anti-TNFα treatment demonstrated a rapid but 
transient increase in SARM expression 
As TNFα blockade is reported to lower IL-1β in addition to neutralizing the effects of 
TNFα, SARM protein expression during the initiation of anti-TNFα biological therapy 
was investigated in RA peripheral blood monocytes [3, 4, 24]. Samples were 
collected at three time points, T1 (prior to anti-TNF treatment), T2 (24 h following 
initiation of treatment) and T3 (3 months after initiation of anti-TNF treatment). 












Thus, the patient responses to treatment were recorded according to the European 
League Against Rheumatism (EULAR) response criteria [26]. Three patients 
displayed no response to treatment, whilst three showed an improvement by T3 
(Fig.5A). In the patients where no improvement of the DAS28 was evident, SARM 
expression was not increased between T1, T2 or T3 (Fig. 5B). However, for patients 
where a good or moderate response was detected, SARM was transiently increased 













Activation of the NLRP3 inflammasome and consequent downstream release of IL-
1β could contribute to several aspects of RA pathogenesis. IL-1β has long been 
associated with bone and cartilage damage in RA joints, through activation of 
chondrocytes and osteoclasts [21]. However, more recently IL-1β has also been 
suggested to have a role in RA comorbidities such as type 2 diabetes and 
cardiovascular disease [27]. In a recent, randomised controlled trial, anakinra (a 
human IL-1 receptor antagonist) was found to reduce the percentage of glycated 
haemoglobin in RA patients with type 2 diabetes [28]. Furthermore, improvements in 
cardiac function have also been reported in RA patients treated with anakinra [29]. 
 
Since the discovery of the NLRP3 inflammasome, a more detailed understanding of 
IL-1β production in RA has evolved. In the collagen induced arthritis model, 
treatment with MCC950, a selective inhibitor of NLRP3, reduces IL-1β, synovial 
inflammation and cartilage erosion [30]. In human studies, components of the 
NLRP3 inflammasome are reported to be increased in RA peripheral blood 
mononuclear cells and ACPAs present in the sera of some RA patients can stimulate 
NLRP3 dependent IL-1β release [17, 31]. Furthermore, incubation of RA synovial 
biopsies cultured with MCC950 is reported to reduce IL-1β [32]. However, the 
contribution of negative feedback mechanisms controlling activation of the NLRP3 
inflammasome have yet to be examined in the context of RA pathophysiology. 
Recently, SARM was identified as a negative regulator of NLRP3, inhibiting the 
recruitment of ASC and consequent inflammasome assembly [12]. Here, our study 












monocytes, elevated disease activity and increased IL-1β production. In keeping with 
its role as a regulator of IL-1β release, low SARM expression in RA monocytes 
correlated with enhanced IL-1β secretion upon TLR1/2 stimulation with Pam3CSK4. 
However, increased IL-1β was not observed upon TLR stimulation with LPS or R-
848 compared to HCs. Initially it was not clear why increased IL-1β was only evident 
upon TLR1/2 activation as in murine bone marrow derived macrophages SARM 
deficiency leads to an increase in IL-1β release upon activation with LPS or 
Pam3CSK4 [12]. However, upon further investigation of human monocytes, SARM 
was found to be upregulated at the message level in response to TLR stimulation 
with LPS and R-848 but not with Pam3CSK4.  
This suggested a negative feedback role for SARM that was absent following TLR1/2 
activation in human monocytes. Thus, RA monocytes from patients with active 
disease, which have a lower basal level of SARM compared to HC monocytes, could 
therefore release greater IL-1β upon TLR1/2 stimulation. Whereas upon stimulation 
with LPS or R-848, upregulation of SARM may compensate for this low basal 
expression, restoring IL-1β to a comparable level to HC monocytes. This data 
revealed the potential for TLR2 on monocytes to contribute to RA pathology through 
increased IL-1β production. It is in keeping with other studies suggesting a role for 
TLR2 in RA. TLR2 expression has been shown to be increased in both circulating 
monocytes and macrophages in the synovial joint [33]. We have previously 
demonstrated elevated TLR2 induced TNFα and IL-6 from RA monocytes [34]. 
Whilst activation of TLR2 in RA synovial fibroblasts leads to increased cell migration, 
invasion and glycolytic activity [35, 36]. Furthermore, addition of a TLR2 neutralizing 
antibody has been shown to reduce spontaneous cytokine production including IL-1β 












Investigation of the expression of the inflammasome components revealed that 
despite NLRP3, CASP1 and PYCARD being reported to be increased in peripheral 
blood mononuclear cells from RA patients, this was not the case for the purified 
monocytes studied here [31]. Although both studies demonstrated a spread in the 
level of expression within the RA patient samples, in this study although a trend 
towards increased expression was observed, this did not reach significance. 
However, SARM1 levels were significantly higher in the RA patients compared to 
HCs, but curiously, this did not equate to the presence of higher protein levels. 
SARM1 expression did inversely correlate with RA disease activity but SARM protein 
was almost undetectable by western blot in most patients with active disease. 
However, monocytes from RA patients in remission (DAS28 <2.6), exhibited a 
comparable level of SARM to HCs.  
This discrepancy in the mRNA and protein expression may reflect post-
transcriptional control, possibly by non-coding RNAs. Indeed, the finding that 
patients who were responsive to anti-TNFα biologics had a transient increase in 
SARM, may indicate a regulatory mechanism downstream of TNFα. Inhibition of 
TNFα in RA patients is reported to decrease the level of other inflammatory 
cytokines, including IL-1β, in addition to its effects on TNFα [3-5]. Thus, the 
downstream regulation of SARM expression by TNFα biologics in patients that 
respond to treatment may explain the additional suppressive effect on IL-1β. 
Biological therapies blocking TNFα are far more effective in RA than those that 
inhibit the action of IL-1β, most likely due to an upstream role of TNFα in regulating 
inflammation [6]. However, this does not preclude a functional role for IL-1β in RA 
pathogenesis. Indeed, a study in a human TNF transgenic arthritis model suggested 












next be important to develop an understanding of how SARM protein expression is 
regulated in RA, as this may have relevance to RA comorbidities and other diseases 
where NLRP3 activation and excess IL-1β are associated with disease pathology, 
such as cardiovascular disease, type 2 diabetes and Alzheimer’s disease [39].  
Overall, this study suggests the potential for SARM to contribute to IL-1β production 
and disease activity in RA. A limitation of this study was that it was not possible to 
directly modulate SARM expression in the patient monocytes, there are currently no 
inhibitors available and genetic manipulation of primary monocytes is not feasible 
due to their short viability in culture. However, the data demonstrate that SARM 
protein expression is lower in RA monocytes from patients with active disease and 
could promote RA pathogenesis by lowering the inhibitory action of SARM on 
TLR1/2 induced IL-1β production. Furthermore, these results reveal a possible 
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Figure 1. TLR1/2 activation induces higher IL-1β secretion from RA patient 
monocytes than healthy controls.  CD14+ monocytes were isolated from peripheral 
blood donated by healthy controls (HC) and rheumatoid arthritis (RA) patients. IL-1β 
secretion was measured following 24h of culture with media alone (Unstimulated) 
and (A) 100ng/ml Pam3CSK4 (HC n=18; RA n= 28), (B) 10ng/ml LPS (HC n=21; RA 
n=29) or (C) 2μg/ml R-848 (HC n=22; RA n=28). Significance was tested using two-
























Figure 2. SARM mRNA expression is elevated in RA monocytes. Monocytes 
were isolated from whole blood collected from healthy controls (HC) and rheumatoid 
arthritis patients (RA). RNA was extracted and the expression of (A) NLRP3 (HC 
n=11; RA n=23), (B) CASP1 (HC n=15; RA n=40), (C) PYCARD (HC n=15; RA 
n=40) and (D) SARM1 (HC n=15; RA n=31) were measured by quantitative PCR. 














Figure 3. SARM expression negatively correlates with IL-1β secretion following 
TLR1/2 stimulation in RA monocytes.  TLR1/2 induced IL-1β secretion was 
measured following 24h of stimulation with 100ng/ml Pam3CSK4 and correlated with 
the basal expression of (A) NLRP3 (n=22), (B) CASP1 (n=22), (C) PYCARD (n=22) 
and (D) SARM1 (n=22) in monocytes from RA patients. The significance was 
analysed using a two-tailed Spearman test. (E) Monocyte IL1B expression following 
a 3h stimulation with 100ng/ml Pam3CSK4 was compared to basal SARM1 
expression (prior to stimulation) in matched patient samples (n=12). (F) Monocytes 
from healthy volunteers (n=7) were stimulated for 6h with 100ng/ml Pam3CSK4, 
10ng/ml LPS or 2µg/ml R-848. SARM1 expression was expressed as the fold 
change from unstimulated cells (US). A one-way ANOVA using Dunnett´s multiple 


























Figure 4. SARM expression by rheumatoid arthritis monocytes inversely 
correlates with disease activity. Expression of (A) SARM1 (n=22), (B) PYCARD 
(n=22), (C) CASP1 (n=22) and (D) NLRP3 (n=22) in monocytes isolated from 
rheumatoid arthritis (RA) patients correlated to the disease activity score in 28 joints 
(DAS28). Significance was analysed using a two-tailed Pearson’s test (*P=0.0246). 
(E) SARM protein expression in monocytes from healthy controls (HC) and RA 
patients with a range of DAS28 scores was analysed by Western blot with GAPDH 













Figure 5.  SARM protein expression is increased in patients that responded to 
anti-TNFα therapy. Patients starting anti-TNFα treatment were monitored at three-
time points; pre-therapy (T1), 24h post therapy (T2) and 3 months post therapy (T3). 
(A) At each time point the disease activity score in 28 joints (DAS28) was measured 
(n=6). A paired students t-test was used to test significance (**P=0.0125). The level 
of SARM protein expression was also measured by Western blot at these time points 
in (B) patients that did not respond to the anti-TNFα therapy (n=3) and (C) in those 
that did respond with a reduction in DAS28 score (n=3). GAPDH was used as a 













Table 1: Demographics, clinical data and treatment modalities of study 
participants. Abbreviations: DAS28, disease activity score 28; csDMARDs, 
conventional synthetic disease-modifying antirheumatic drug; SZP, sulfasalazine; 
HCQ, hydroxychloroquine; AZA, azathioprine; LEF, leflunomide; bDMARDs, 
biological disease-modifying antirheumatic drugs; NSAIDs, nonsteroidal anti-
inflammatory drugs. 
Characteristics Value 
Healthy controls (n) 27 
Age (years, mean ±SD) 44.6 ±11.53 
Sex (male:female) 3:23 (1 unknown) 
Rheumatoid arthritis (n) 99 
Age (years, mean ±SD) 57.48 ±15.06 
Sex (male:female) 24:75 
DAS28 (mean ±SD) 4.51 ±1.83 
Disease duration (years, mean ±SD) 12.36 ±12.76 
Medication of rheumatoid arthritis patients Value, n (%) 
csDMARDs 72 (72.7%) 
Methotrexate 41 (41.4%) 
Other csDMARDs (SZP, HCQ, AZA, LEF)  18 (18.2%) 
Methotrexate and other csDMARDs 19 (19.2%) 
bDMARDs 14 (14.1%) 
TNF-α inhibitor  11 (11.1%) 
Other bDMARDs (IL-6 inhibitor, anti-CD20) 2 (2.0%) 












NSAIDs 10 (10.1%) 
Glucocorticoids 26 (26.3%) 
Antidepressants 1 (1.0%) 
Analgesics 1 (1.0%) 
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